Innovive Pharmaceuticals Announces Data from Oncology Drug Programs to be Presented at American Association for Cancer Research Annual Meeting
Information related to these presentations is as follows: -0-
Presentation Title: "A phase I study of INNO-406, a dual inhibitor
of Abl/Lyn kinases, in adult patients with
imatinib-resistant or intolerant Philadelphia
chromosome positive (Ph+) leukemias"
----------------------- ----------------------------------------------
Abstract Number: 2637
----------------------- ----------------------------------------------
Session: Poster Section 5, Clinical Research 11, Poster
Board #2
----------------------- ----------------------------------------------
Session Date and Time: Monday, April 16, 2007, 1:00 p.m. - 5:00 p.m.
----------------------- ----------------------------------------------
Location: Exhibit Hall, Los Angeles Convention Center
----------------------- ----------------------------------------------
----------------------- ----------------------------------------------
Presentation Title: "Reduced chronic cardiotoxicity and
mitochondrial damage of the (6-
maleimidocaproyl) hydrazone derivative of
doxorubicin (DOXO-EMCH) in a rat model
compared to doxorubicin"
----------------------- ----------------------------------------------
Abstract Number: 5587
----------------------- ----------------------------------------------
Session: Poster Section 28, Experimental and Molecular
Therapeutics 46, Poster Board #10
----------------------- ----------------------------------------------
Session Date and Time: Wednesday, April 18, 2007, 8:00 a.m. - 12:00
p.m.
----------------------- ----------------------------------------------
Location: Exhibit Hall, Los Angeles Convention Center
----------------------- ----------------------------------------------
About INNO-406
INNO-406 (formerly known as NS-187) is an orally bioavailable, rationally designed, dual Bcr-Abl and Lyn-kinase inhibitor currently in Phase I clinical studies. According to a study published in the journal Blood (Dec. 1, 2005), INNO-406 is 25 to 55 times more potent than imatinib in vitro, and at least 10 times as effective as imatinib mesylate in suppressing the growth of Bcr-Abl bearing tumors. INNO-406 has demonstrated activity in 12 of 13 imatinib-resistant cell lines. In addition to its Bcr-Abl inhibitory properties, INNO-406 inhibits Lyn kinase. Upregulation of Lyn kinase activity is a well recognized cause of imatinib resistance. Lyn kinase activation has also been documented in a variety of solid tumors, including prostate cancer.
About INNO-206
INNO-206 (formerly DOXO-EMCH) is a doxorubicin prodrug designed to preferentially reach the tumor and reduce adverse events compared to native doxorubicin. A Phase I study of INNO-206 that demonstrated safety and objective clinical responses in a variety of tumor types was completed in 2005 and presented at the March 2006 Krebskongress meeting in Berlin. In this study, doses were administered at up to six times the standard dosing of doxorubicin without an increase in observed side effects over historically seen levels with doxorubicin. Objective clinical responses were seen in patients with sarcoma, breast, and lung cancers.
About INNOVIVE Pharmaceuticals
INNOVIVE Pharmaceuticals, Inc. acquires, develops and commercializes novel therapeutics addressing significant unmet medical needs in the fields of oncology and hematology. The company has four drug programs in clinical development: INNO-406, Tamibarotene, INNO-206, and INNO-305, for the treatment of chronic myelogenous leukemia, acute promyelocytic leukemia, small cell lung cancer, and acute myelogenous leukemia, respectively. For additional information visit www.innovivepharma.com.
Contact
INNOVIVE Pharmaceuticals
Steve Kelly
President and CEO
212-716-1820
or
Porter Novelli Life Sciences
Media & Investor Relations
Rachel Lipsitz
619-849-5378
Posted: April 2007
